Evidence map›Paper›PMID 37470971›Full record

ReviewPulmonary therapy2023

The 2023 GOLD Report: Updated Guidelines for Inhaled Pharmacological Therapy in Patients with Stable COPD.

Paul D Terry, Rajiv Dhand

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pulmonary therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Diagnosis and Severity Assessment of COPD Based on Machine Learning of Chest CT Images.International journal of chronic obstructive pulmonary disease · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Real-World Use of Inhaled COPD Medications: the Good, the Bad, the Ugly.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Paul D TerryDepartment of Medicine, Graduate School of Medicine, University of Tennessee Medical Center, 1924 Alcoa Highway, Box U-114, Knoxville, TN, 37920, USA.
Rajiv DhandDepartment of Medicine, Graduate School of Medicine, University of Tennessee Medical Center, 1924 Alcoa Highway, Box U-114, Knoxville, TN, 37920, USA. rdhand@utmck.edu.ORCID http://orcid.org/0000-0002-3621-2422
University of Tennessee Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past 22 years, annual GOLD Reports have documented important changes in guidance and recommendations for uniformly treating patients with chronic obstructive pulmonary disease (COPD) with the goal of improving outcomes in patients suffering from this condition. The most recent GOLD Report, released in 2023, shows continued refinement in several areas, including more precise definitions of COPD and exacerbations of COPD, a new set of parameters to assess exacerbation severity, an updated COPD assessment tool, updated guidelines for initial and follow-up treatment, new information regarding the association between pharmacological triple therapy and reduction in mortality, and new discussions of inhaler device choice and adherence to COPD medications. Whereas we do not address all of the new or updated material in GOLD's 2023 Report, we summarize key changes in GOLD's recommendations regarding inhalation therapy for stable COPD and frame these changes in the context of previous GOLD recommendations.

Indexed as

Adherence to therapyCOPDCOPD treatmentGOLD reportsInhaled pharmacotherapeutics

Identifiers

PMID37470971
PMCPMC10447769
OpenAlexW4384820161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.